SEC Company Response from ABBOTT LABORATORIES (ABT) — Feb 4, 2022
ABBOTT LABORATORIES
Date: Feb. 4, 2022 · CIK: 0000001800 · Accession: 0001104659-22-012162
AI Filing Summary & Sentiment
File numbers found in text: 001-02189
Letter
United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Margaret Schwartz Christopher Edwards RE: File No. 001-02189
Dear Ms. Schwartz and Mr. Edwards:
In reply to your letter of December 23, 2021, we supplement our response to Comment 2 submitted on January 31, 2022 as follows:
From time to time, Abbott has experienced isolated weather-related damages to some of its property or operations. However, the impact of such damages has not been material. In 2020, such damages constituted less than 1% of total operating expenses.
Very truly yours,
/s/ Robert E. Funck, Jr.
Show Raw Text
CORRESP
1
filename1.htm
February 4, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street NE
Washington, D.C. 20549
Attention:
Margaret Schwartz
Christopher Edwards
RE: File No. 001-02189
Dear Ms. Schwartz and Mr. Edwards:
In reply to your letter of December 23, 2021, we supplement our response
to Comment 2 submitted on January 31, 2022 as follows:
From time to time, Abbott has experienced isolated weather-related
damages to some of its property or operations. However, the impact of such damages has not been material. In 2020, such damages constituted
less than 1% of total operating expenses.
Very truly yours,
/s/ Robert E. Funck, Jr.
Robert E. Funck, Jr.
Executive Vice President, Finance and Chief Financial Officer